Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-819
- Development stage
- Preclinical
- Lead developer
- Neurosterix
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
NTX-819 is a small molecule negative allosteric modulator (NAM) of the metabotropic glutamate receptor 7 (mGlu7), currently under development by Neurosterix Pharma. The drug is in the IND-enabling phase for the treatment of mood disorders and anxiety disorders. By binding to an allosteric site on the mGlu7 receptor, NTX-819 reduces the receptor's response to glutamate, thereby modulating excitatory signaling in the central nervous system. This mechanism is hypothesized to provide therapeutic benefits in neuropsychiatric conditions where mGlu7 signaling is implicated in the pathophysiology of stress and emotional regulation. Neurosterix Pharma, a CNS-focused company, is advancing NTX-819 as part of its pipeline of allosteric modulators for neuropsychiatric and neurological conditions.
02
Targets
Beyond the preview
Go deeper on NTX-819.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-819.